Demands for government action grow amid mounting pressures on health care; Opill offers convenient access to contraception without a prescription; the White House announces progress as drugmakers submit counteroffers for Medicare’s drug price negotiation program.
Health Care Providers Call on Federal Intervention to Address Cyber Outages
UnitedHealth Group's handling of the ransomware attack on its subsidiary, Change Healthcare, has drawn sharp criticism from health care providers, prompting calls for urgent government intervention, according to Axios. With payment systems paralyzed, hospitals and medical associations have warned of dangerous cash shortages, demanding immediate action from the Biden administration to alleviate the crisis. As pressure mounts on UnitedHealth Group to address the fallout, stakeholders are urging HHS to step in as well.
Birth Control Pill Opill Set to Hit US Stores This Month
Perrigo has announced the soon-to-be availability of Opill, the first over-the-counter birth control pill in the US, according to The Associated Press. With no age restrictions and priced affordably at $20 for a on1e-month supply, Opill will offer a convenient alternative amid ongoing legal battles over reproductive health rights. The launch marks a significant milestone in expanding access to birth control options and comes during a period of broader debate surrounding reproductive rights in the US.
Drug Manufacturers Engage in Medicare Price Negotiations Despite Legal Challenges
President Biden has confirmed that all manufacturers involved in the federal government's Medicare price negotiation program have submitted counteroffers, marking a significant milestone in efforts to lower prescription drug costs, according to The Hill. Despite legal battles from the pharmaceutical industry, negotiations continue for the first 10 selected drugs, with talks set to conclude on August 1. The development underscores ongoing efforts to address rising health care expenses and provide older Americans with more affordable medication options.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Frameworks for Advancing Health Equity: Pharmacy Support for Non-Hodgkin Lymphoma
December 19th 2024Rachael Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with insurance companies and providers to support treatment access for patients with non-Hodgkin lymphoma.
Listen
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More